公开(公告)号：US20240355443A1

公开(公告)日：2024-10-24

申请号：US18602287

申请日：2024-03-12

申请人： Tata Consultancy Services Limited

发明人： Tungadri BOSE ,  Harrisham KAUR ,  Rashmi SINGH ,  Anirban DUTTA ,  Mohammed Monzoorul HAQUE ,  Sharmila Shekhar MANDE

IPC分类号： G16H20/10 ,  G06N20/20 ,  G16H10/40 ,  G16H10/60 ,  G16H50/30 ,  G16H50/70

CPC分类号： G16H20/10 ,  G06N20/20 ,  G16H10/40 ,  G16H10/60 ,  G16H50/30 ,  G16H50/70

摘要： The present disclosure is related to a method and system for stratification of subjects as one of responders or non-responders to a therapy. It is imperative to critically evaluate the baseline/initial microbiome structure and composition of individuals and stratifying them before prescribing any microbiome-based drug/dietary interventions. The method identifies a panel of biological features/indicators/markers/signatures that can accurately stratify/classify/group individuals into responders and non-responders (for a given microbiome-based drug/therapy) based upon the differences in the metabolic functions of the gut microbial communities between the baseline gut microbiome profile (i.e. before the administration of an intervention) and after treatment gut microbiome profile (i.e. after the administration of the intervention). Individuals with samples showing an improvement in gut-health status after the administration of the pre-biotic intervention were tagged as responders and the rest were tagged as non-responders.

公开(公告)号：US20220328192A1

公开(公告)日：2022-10-13

申请号：US17634634

申请日：2020-08-12

申请人： Tata Consultancy Services Limited

发明人： Sharmila Shekhar MANDE ,  Tungadri BOSE ,  Subhrajit BHAR ,  Rashmi SINGH ,  Nishal Kumar PINNA

IPC分类号： G16H50/30 ,  G16B25/10 ,  G16B30/10 ,  G16B40/20

摘要： Schizophrenia is a chronic and severe psychiatric disorder that affects how a person thinks, feels, and behaves. If Schizophrenia is diagnosed early, most symptoms of Schizophrenia can be managed with appropriate medical interventions. A system and method for assessing the risk of Schizophrenia in a person has been provided. The system is configured to assess individuals to check the presence or absence of Schizophrenia, by quantifying the abundance of sensory proteins in their microbiome. The disclosure relates to a defined methodology that involves assessment and categorization of the person into healthy and schizophrenic based on the abundance of sensory proteins in the microbiome. The systems and methods further describe microbiota based therapeutics for management of Schizophrenia through generating a therapeutic model and administering a consortium of healthy microbes which could modulate the disease microbiome composition towards a healthy equilibrium.